Inside ESMO 2024: Treatments, Trials, and Top HCPs on Social Media

The European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona was a pivotal event for the oncology community, attracting over 34,000 attendees from around the globe. The congress served as a platform for discussing the latest advancements in cancer treatments, trials, and research.

Healthcare professionals (HCPs) utilized social media extensively to share and amplify the latest scientific data presented at the congress. A total of 15,755 posts were made by 1,673 individual HCPs, with 28 ESMO Ambassadors contributing 1,710 posts across X and LinkedIn.

Key Highlights from ESMO 2024

• AMBASSADOR Study: Focused on bladder cancer, this study highlighted the effectiveness of pembrolizumab as an adjuvant treatment, showing impressive results in disease-free survival rates.
• NIAGARA Trial: This phase 3 trial by AstraZeneca assessed the combination of durvalumab with cisplatin and gemcitabine for muscle-invasive bladder cancer, with results described as "practice changing".
• ADRIATIC Trial: Discussed in over 253 posts, this trial showcased the progression-free survival benefits of durvalumab in limited-stage small cell lung cancer.
• MARIPOSA-2 Study: Highlighted by ESMO Ambassador Antonio Passaro, this study presented a promising overall survival trend for amivantamab plus chemotherapy in non-small cell lung cancer (NSCLC).
• NATALEE Trial: This trial underscored the long-term benefits of adjuvant ribociclib in early breast cancer, with 16 HCPs sharing news of the FDA's approval of the drug in combination with an aromatase inhibitor (AI).

Most Discussed Cancer Types

• Genitourinary (GU) Cancer: Accounted for 12% of online conversations, with significant attention on trials like AMBASSADOR.
• Lung Cancer: The second most discussed, with over 1,600 posts, largely focusing on the ADRIATIC trial.
• Breast Cancer: Despite being the third most discussed, it generated the largest number of original HCP posts, particularly around the NATALEE trial.

Influential Voices

• Dr. Gil Morgan: The most active HCP, reposting 857 times with an average reach of over 6,000 per post.
• Dr. Gilberto Lopes: Ranked second for post volume, with the highest average reach of over 10,000 per post.
• ESMO Ambassadors: Collectively, they had a total HCP following of more than 26,000, significantly influencing online conversations during the congress.

ESMO 2024 not only showcased the latest in oncology but also demonstrated the power of social media in disseminating critical scientific advancements to a global audience.